The book comprehensively reviews and provides detailed insight into the cellular and molecular signalling mechanisms involved in pathophysiology of various respiratory diseases, towards developing effective therapeutic strategies in the management and treatment of lung disease. It also covers promising advances in the field of therapeutics that could lead to novel clinical therapies capable of preventing or reversing the disease features including novel strategies for targeting chronic lung diseases using advanced drug delivery systems. Importantly, the book examines the significance and relevance of the plant extracts and their constituents with therapeutic efficiencies against lung diseases. As such, the book offers a blend of translational, biological, chemical, and drug delivery aspects relevant to respiratory diseases, thus, offering a valuable resource for pulmonologists and translational researchers working in the field of pulmonary biology and respiratory medicine.
Chapter 1. Introduction to Lung Diseases.- Chapter 2. Targeting
molecular and cellular mechanisms in asthma.-Chapter 3. Various cellular and
molecular axis involved in the pathogenesis of asthma.
Chapter 4. Targeting
molecular and cellular mechanisms in steroid resistant asthma.- Chapter
5. Targeting molecular and cellular mechanisms in chronic obstructive
pulmonary disease.- Chapter 6. Probing the cellular and molecular mechanisms
underlying in the pathogenesis of Chronic Obstructive Pulmonary Disease
(COPD).- Chapter 7. Chronic obstructive pulmonary disease: Molecular basis of
pathogenesis and targeted therapeutic approaches.- Chapter 8. Exploring the
dormancy-activation switch in the tumour microenvironment for metastatic
lung cancer: The possible role of microRNA.- Chapter 9. Therapeutic
strategies targeting signalling pathways in lung cancer.- Chapter
10. Modulation of signalling pathways byimmunotherapeutics in lung
cancer.- Chapter 11. Underpinning the Cellular and Molecular Mechanisms with
Nanotheronstics for Lung Cancer.- Chapter 12. Targeting molecular and
cellular mechanisms in Idiopathic Pulmonary Fibrosis.-Chapter 13. A refined
approach to target the molecular and cellular mechanisms in pulmonary
fibrosis.-Chapter 14. Targeting molecular and cellular mechanisms in
tuberculosis.
Chapter 15. Cellular and Molecular Mechanisms of Repurposed
antidiabetic drug as adjunctive treatment for tuberculosis.
Chapter
16. Targeting host and bacterial signaling pathways in tuberculosis: An
effective strategy for the development of novel anti-tubercular therapies.-
Chapter 17. Targeting molecular and cellular mechanisms in pulmonary
hypertension.
Chapter 18. Targeting molecular and cellular mechanisms in
pulmonary arterial hypertension.
Chapter 19. Potential cellular targets
associated with the signaling and therapeutics of the pulmonary
hypertension.
Chapter 20. Targeting molecular and cellular mechanisms in
influenza A virus infections.
Chapter 21. Understanding the Biology of
Non-typeable Haemophilus influenzae in Chronic Obstructive Pulmonary Disease
through the Lens of Genomics.
Chapter 22. Targeting molecular and cellular
mechanisms in rhinovirus infection.
Chapter 23. Targeting molecular and
cellular mechanisms in respiratory syncytial virus (RSV) infection.
Chapter
24. Targeting molecular and cellular mechanisms SARS-CoV2 novel corona
(COVID-19) virus infection.
Chapter 25. Underpinning the rudimentary
mechanisms involved in the pathogenesis of SARS-CoV2 (COVID-19) in human lung
cells.
Chapter 26. Targeting molecular and cellular mechanisms in SARS-CoV2
novel corona (COVID-19) virus infection.
Chapter 27. Special features of
human lung ACE2 sensitivity to SARS CoV-2 spike glycoprotein.
Chapter
28. Implications of Phosphoinositide 3-kinase (PI3K) Signalling in cellular
and molecular mechanisms of respiratory diseases.
Chapter 29. The role of
the cholinergic system in lung diseases.
Chapter 30. The Nrf2-Keap1
signaling pathway in lung cancer.
Chapter 31. Role of Toll like receptor
(LTR) in molecular and cellular mechanism of respiratory diseases.
Chapter
32. Biomarkers of Oxidative Stress.
Chapter 33. Targeting chronic lung
diseases using advanced drug delivery systems.
Chapter 34. Plant based
chemical moieties targeting cellular signalling pathways in chronic lung
diseases.
Chapter 35. Role of phytoconstituents in targeting cytokines for
managing pathophysiology of lung diseases.
Chapter 36. Targeting Cellular
Signaling Pathways in Lung Cancer and Role of Phytochemicals as Novel
Therapeutic Approach.
Chapter 37. Natural compounds targeting major
signalling pathways in lung cancer.
Chapter 38. Drug delivery in respiratory
diseases: Current opportunities, Molecular and cellular mechanism, and
Future challenges.
Chapter 39. Future prospects and challenges in targeting
cellular and molecular mechanisms in respiratory diseases.
Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 12 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Duas research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.
Raimar Löbenberg holds a BS in Pharmacy from the Johannes Gutenberg-University in Mainz, Germany, and received his PhD in Pharmaceutics from the Johann Wolfgang Goethe-University. His research interests are in Biopharmaceutics and inhalable nanoparticles to treat lung diseases. He is a founder and Director of the Drug Development and Innovation Centre at the University of Alberta. He was president of the Canadian Society for Pharmaceutical Sciences 20142015 and a member of the United States Pharmacopeia Dietary Supplement Expert Committee. He is a Vice-chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science. He is a member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology.
Ângela Cristina Malheiros Luzo is a full Professor from the Surgical Science Post Graduation Discipline at the Faculty of Medical Science Surgery Department, UNICAMP. She is an active researcher at the Biology Institute of the State University of Campinas (UNICAMP). She served as a member of the liver transplantation team and was responsible for the installation of the Umbilical Cord Blood Bank (BSCUP) at UNICAMP. She obtained her medical degree from Faculty of Medical Sciences of Jundiaí and holds Masters and PhD degrees in the field of biology and cell therapy of umbilical cord blood stem cells from the Clinical Medicine Department of the Faculty of Medical Science, UNICAMP. She has three licensed patents related to fibrin glue that allows the attachment of mesenchymal stromal stem cells in suture filaments providing a complete regeneration of enterocutaneous fistula, tracheal injury, and correction of urethral stenosis in animal models (rat, pig, and rabbit).
Shakti Shukla is a trained microbiologist and completed his PhD in Medical Studies from the University of Tasmania. Dr. Shukla has been actively involved in various aspects of chronic respiratory diseases, including the pathophysiology and immunology of respiratory diseases especially cigarette smoking-related chronic obstructive pulmonary disease (COPD), lung cancer, and asthma. Dr. Shukla's primary research interest involves the crucial role of microorganisms, in particular bacteria, in the development, progression, and exacerbations of COPD/asthma. His more recent research focuses on understanding the role of gastrointestinal microbiomes in the progression of COPD and whether the gut microbes could be utilized as a potential treatment for COPD. Dr. Shukla has published more than 65 publications in the last 6 years and has won Young Investigator Award from Thoracic Society of Australia and New Zealand (Tasmania Branch) for his research.
Saurabh Satija is currently working as Assistant Dean at School of Pharmaceutical Sciences and Division of Student Welfare, Lovely Professional University (LPU), India, and also an academic with Discipline of Pharmacy, Graduate School of Health, University of Technology, Sydney, Australia. He has extensive experience in the field of natural products research, drug development, analytical method development, and nanotechnology-based novel drug delivery systems. He has received various national and international awards, scholarships, and research grants. He also carries an impressive bibliography of scientific papers published in journals of international repute. He has more than 100 research publications and two patents published to his credit.
